( LCBM) were among the worst-performing health-related stocks Thursday, falling 15% after the medical-device maker posted third-quarter earnings that topped expectations but warned that fourth-quarter sales would be below expectations.
The company posted earnings of $2.1 million, or 15 cents a share, on sales of $14.1 million. Favorable foreign currency translation added $102,000 to its sales results. Analysts surveyed by Thomson First Call were expecting earnings of 14 cents a share on sales of $14 million. Looking ahead, Lifecore forecast in-line fourth-quarter earnings of 13 cents to 15 cents a share on sales of $13.8 million to $14.2 million. Analysts had been expecting earnings of 14 cents a share on sales of $14.4 million. For all of 2005, Lifecore upped its earnings guidance to 56 cents to 58 cents a share on sales growth of 15% to 16%, or $54.05 million to $54.52 million. Analysts are expecting earnings of 56 cents a share on sales of $54.67 million. Shares were trading down $2.66 to $14.54.
rose 6% after the company and
( VTIV) signed a sales agreement that will add to Connetics' sales results during 2005 and add to earnings and sales in 2006. As a result of the agreement, which calls for Ventiv to market and promote Connetics' dermatology products to about 8,000 physicians, Connetics raised its 2005 sales outlook. It now expects sales of $195 million to $206 million, up from previous guidance of $190 million to $200 million. Analysts had been expecting 2005 sales of $195.6 million. The agreement is expected to add about $12 million to $14 million to 2006 sales results and add about 8 cents to 10 a share. Ventiv will begin selling the products on April 18. Shares of Connetics were trading up $1.61 to $27.28.
( MOGN) fell 8% after the company posted first-quarter earnings and sales that fell below expectations. The drug company posted earnings of $11.6 million, or 15 cents a share, on sales of $63.2 million. Analysts were expecting earnings of 16 cents a share on sales of $66.2 million. Looking ahead, MGI Pharma put 2005 income from operations at about $62 million on sales of around $285 million. Analysts are expecting earnings of 77 cents a share on sales of $287.1 million. Shares were trading down $2 to $23.92.
rose 7% after the company said the Food and Drug Administration granted Panzem, the company's lead compound for the treatment of ovarian cancer, orphan drug status. The orphan status designation allows Entremed to receive prefiling regulatory guidance, reduced fees and provides market exclusivity for seven years once the FDA approves the drug. Panzem has already received orphan status as a treatment for multiple myeloma, a type of blood cancer. Shares were trading up 18 cents to $2.87.
Other health care movers included
, up 24 cents to $27.52;
( SGP), up 75 cents to $20.65;
, down 87 cents to $56.25;
, down 18 cents to $4.11;
( WYE), up 50 cents to $44.91;
, up 26 cents to $34.78;
, down $3.40 to $60.11;
, up 21 cents to $25.99;
, down 35 cents to $60.12; and
Johnson & Johnson
, up 34 cents to $68.93.